Vera Gelbricht

1.0k total citations · 1 hit paper
13 papers, 751 citations indexed

About

Vera Gelbricht is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Vera Gelbricht has authored 13 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 7 papers in Internal Medicine and 1 paper in Surgery. Recurrent topics in Vera Gelbricht's work include Atrial Fibrillation Management and Outcomes (13 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Cardiac Arrhythmias and Treatments (4 papers). Vera Gelbricht is often cited by papers focused on Atrial Fibrillation Management and Outcomes (13 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Cardiac Arrhythmias and Treatments (4 papers). Vera Gelbricht collaborates with scholars based in Germany and United States. Vera Gelbricht's co-authors include Sebastian Werth, Christina Köhler, Jan Beyer‐Westendorf, Luise Tittl, Franziska Ebertz, Franziska Michalski, Sven Pannach, Kurtuluş Şahin, Katharina Daschkow and Norbert Weiss and has published in prestigious journals such as Blood, European Heart Journal and Thrombosis and Haemostasis.

In The Last Decade

Vera Gelbricht

13 papers receiving 731 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

2014 311 citations Jan Beyer‐Westendorf, Sven Pannach et al. Blood profile →

Peers

Vera Gelbricht

CCM

IM

SURGE

HEMAT

EPIDE

Chern En Chiang Taiwan

Masahiro Tajiri Japan

Franziska Michalski Germany

Sandra Marten Germany

Jim Douketis Canada

Janice Castillo United States

Franziska Ebertz Germany

Annya Stephens-Boal United Kingdom

Pablo Javier Marchena Spain

Michelle Zondag Canada

Chern En Chiang Taiwan

Vera Gelbricht

650 ×0.9

CCM

299 ×0.6

IM

46 ×0.6

SURGE

27 ×0.5

HEMAT

116 ×2.5

EPIDE

Citations per year, relative to Vera Gelbricht Vera Gelbricht (= 1×) peers Chern En Chiang

Countries citing papers authored by Vera Gelbricht

Since Specialization

Citations

This map shows the geographic impact of Vera Gelbricht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vera Gelbricht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vera Gelbricht more than expected).

Fields of papers citing papers by Vera Gelbricht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vera Gelbricht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vera Gelbricht. The network helps show where Vera Gelbricht may publish in the future.

Co-authorship network of co-authors of Vera Gelbricht

This figure shows the co-authorship network connecting the top 25 collaborators of Vera Gelbricht. A scholar is included among the top collaborators of Vera Gelbricht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vera Gelbricht. Vera Gelbricht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Ebertz, Franziska, Vera Gelbricht, Franziska Michalski, et al.. (2015). Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Thrombosis and Haemostasis. 113(6). 1247–1257. 115 indexed citations

2.

Beyer‐Westendorf, Jan, Vera Gelbricht, K. Förster, et al.. (2014). Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. European Heart Journal. 35(28). 1888–1896. 246 indexed citations

3.

Beyer‐Westendorf, Jan, Sven Pannach, Franziska Ebertz, et al.. (2014). Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 124(6). 955–962. 311 indexed citations breakdown →

4.

Beyer‐Westendorf, Jan, Vera Gelbricht, Franziska Ebertz, et al.. (2014). Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry. British Journal of Clinical Pharmacology. 78(4). 908–917. 47 indexed citations

5.

Beyer‐Westendorf, Jan, Franziska Ebertz, Vera Gelbricht, et al.. (2014). Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry. Blood. 124(21). 4264–4264. 2 indexed citations

6.

Ebertz, Franziska, Vera Gelbricht, Luise Tittl, et al.. (2013). Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119). Blood. 122(21). 214–214. 1 indexed citations

7.

Beyer‐Westendorf, Jan, Vera Gelbricht, Kathrin I. Foerster, et al.. (2013). Periinterventional management of novel oral anticoagulants: results of the prospective Dresden NOAC registry. European Heart Journal. 34(suppl 1). P5444–P5444. 2 indexed citations

8.

Beyer‐Westendorf, Jan, Franziska Ebertz, Vera Gelbricht, et al.. (2013). Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119). European Heart Journal. 34(suppl 1). P4870–P4870. 15 indexed citations

9.

Gelbricht, Vera, et al.. (2012). Hair Loss Is a Potential Side Effect of Novel Oral Anticoagulants – Findings From the Dresden Noac Registry (NCT01588119). Blood. 120(21). 1173–1173. 6 indexed citations

10.

Gelbricht, Vera, et al.. (2012). Real Life Efficacy and Safety of Rivaroxaban for Acute VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119). Blood. 120(21). 1159–1159. 1 indexed citations

11.

Werth, Sebastian, et al.. (2012). Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119). Blood. 120(21). 1156–1156. 2 indexed citations

12.

Werth, Sebastian, et al.. (2012). Real Life Efficacy and Safety of Rivaroxaban for Extended VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119).. Blood. 120(21). 2267–2267. 2 indexed citations

13.

Gelbricht, Vera, et al.. (2012). Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119). Blood. 120(21). 502–502. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact